BR100 Decreased By (-0.91%)
BR30 Decreased By (-1.47%)
KSE100 Decreased By (-0.78%)
KSE30 Decreased By (-0.75%)
AGHA 6.67 Decreased By ▼ -0.01 (-0.15%)
BECO 4.35 Decreased By ▼ -0.02 (-0.46%)
BML 56.17 Decreased By ▼ -1.15 (-2.01%)
BOP 30.12 Decreased By ▼ -0.23 (-0.76%)
CNERGY 12.98 Decreased By ▼ -0.14 (-1.07%)
CSIL 5.31 Decreased By ▼ -0.10 (-1.85%)
FCCL 51.65 Decreased By ▼ -1.14 (-2.16%)
FFL 14.49 Decreased By ▼ -0.23 (-1.56%)
FNEL 1.21 Increased By ▲ 0.09 (8.04%)
KEL 6.06 Decreased By ▼ -0.03 (-0.49%)
KOSM 5.84 Increased By ▲ 0.11 (1.92%)
LOTCHEM 26.17 Decreased By ▼ -0.29 (-1.1%)
MLCF 91.23 Decreased By ▼ -1.93 (-2.07%)
NBP 164.19 Decreased By ▼ -0.47 (-0.29%)
NCPL 53.18 Decreased By ▼ -2.48 (-4.46%)
NPL 59.12 Decreased By ▼ -2.04 (-3.34%)
OGDC 313.39 Decreased By ▼ -3.34 (-1.05%)
PACE 9.77 Decreased By ▼ -0.10 (-1.01%)
PAEL 35.24 Decreased By ▼ -0.39 (-1.09%)
PIBTL 14.71 Increased By ▲ 0.03 (0.2%)
PPL 221.36 Decreased By ▼ -5.55 (-2.45%)
PRL 91.22 Decreased By ▼ -1.80 (-1.94%)
PTC 59.19 Decreased By ▼ -1.07 (-1.78%)
SSGC 23.30 Decreased By ▼ -0.51 (-2.14%)
TBL 8.75 No Change ▼ 0.00 (0%)
TELE 7.61 Decreased By ▼ -0.19 (-2.44%)
TPL 22.03 Decreased By ▼ -0.32 (-1.43%)
TPLP 12.56 Decreased By ▼ -0.41 (-3.16%)
TREET 21.73 Decreased By ▼ -0.43 (-1.94%)
TRG 55.79 Decreased By ▼ -0.77 (-1.36%)

ISLAMABAD: The Competition Commission of Pakistan (CCP) has authorised the transaction of Standpharm Pakistan (Private) Limited by Crest Garments International (Private) Limited.

The transaction forms part of an internal corporate restructuring, as both entities are under the common ownership and management of the same group of individual shareholders.

Standpharm Pakistan operates in the pharmaceutical and nutraceutical sectors, offering a diverse product portfolio across nineteen therapeutic categories, including anti-rheumatics, analgesics, vitamins and mineral supplements, gastrointestinal drugs, antibiotics, and psycholeptics, among others.

Crest Garments International, primarily engaged in the garment manufacturing business, has no existing operations in the pharmaceutical or nutraceutical markets.

Following its detailed assessment, the CCP concluded that the proposed acquisition does not give rise to any horizontal, vertical, or conglomerate overlaps between the merging entities and will not result in increased market concentration.

The pharmaceutical and nutraceutical markets in Pakistan remain competitive, with a large number of active players, moderate market concentration, and continued entry of new firms. Therefore, the transaction is not expected to substantially lessen competition or create a dominant position in any relevant market.

The Commission further noted that the transaction constitutes an intra-group restructuring, resulting in no change in ultimate control or management.

The existing market dynamics, competitive pressures, and opportunities for new entrants in the pharmaceutical and nutraceutical sectors will remain unaffected.

Copyright Business Recorder, 2025

Comments

Comments are closed for this article.